2-(3-氨基苯氧基)-N,N-二甲基乙酰胺 | 184944-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(3-氨基苯氧基)-N,N-二甲基乙酰胺
• 英文名称: 2-(3-aminophenoxy)-N,N-dimethylacetamide
• CAS: 184944-88-5
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD09046918
• 分子量: 194.233
• InChiKey: ORVOZEIZAGYCHU-UHFFFAOYSA-N

物化性质

• 沸点：
  379.7±22.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  三光气 、 2-(3-amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-phenylacetamide 、 2-(3-氨基苯氧基)-N,N-二甲基乙酰胺 在 三乙胺 作用下， 生成 2-[3-[[3-[2-(dimethylamino)-2-oxoethoxy]phenyl]carbamoylamino]-2,4-dioxo-5-phenyl-1,5-benzodiazepin-1-yl]-N-phenyl-N-propan-2-ylacetamide
  参考文献：
  名称：

  Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II):  Optimization of the C3 Amino Substituent

  摘要：

  Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC(50) = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist; of CCK-8 (pA(2) = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.

  DOI：

  10.1021/jm9601664
• 作为产物：
  描述：

  N,N-dimethyl-2-(3-nitrophenoxy)acetamide 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 2-(3-氨基苯氧基)-N,N-二甲基乙酰胺
  参考文献：
  名称：

  Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II):  Optimization of the C3 Amino Substituent

  摘要：

  Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC(50) = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist; of CCK-8 (pA(2) = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.

  DOI：

  10.1021/jm9601664

文献信息

• (7H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2597098A1

  公开（公告）日：2013-05-29

  Inhibitors of LIM kinase 2 of the following formula are disclosed, along with pharmaceutical compositions comprising them and methods of their use, in particular for treatment of inflammatory and cancerous and ocular diseases. X is O or NRA; A is cycloalkyl, aryl or heterocyclyl; RA is hydrogen, cyano, nitro, RA1, SO2RA1 or SO2N(RA1)2; each RB is independently hydrogen or alkyl. The other variables are as defined in the claims.

  本研究公开了下式的 LIM 激酶 2 抑制剂，以及包含这些抑制剂的药物组合物和使用方法，尤其是用于治疗炎症、癌症和眼部疾病的方法。 X 是 O 或 NRA； A 是环烷基、芳基或杂环基； RA 是氢、氰基、硝基、RA1、SO2RA1 或 SO2N(RA1)2 每个 RB 独立地为氢或烷基。 其他变量如权利要求中所定义。
• (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2188289B1

  公开（公告）日：2015-10-28
• [EN] KINASE INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE KINASE, COMPOSITIONS LES CONTENANT ET PROCÉDÉS D'UTILISATION
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2009021169A2

  公开（公告）日：2009-02-12

  Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions com πsin them and methods of their use. X is O or NRA; Y is O, NRR, or C(RR)2; A is cycloalkyl, aryl or hctcrocyclc; RA is hydrogen, cyano, nitro, RA1, SO2RA1, SO2NRA1, or SO2N(RA1)2;
• Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II):  Optimization of the C3 Amino Substituent
  作者：Gavin C. Hirst、Christopher Aquino、Lawrence Birkemo、Dallas K. Croom、Milana Dezube、Robert W. Dougherty,、Gregory N. Ervin、Mary K. Grizzle、Brad Henke、Michael K. James、Michael F. Johnson、Tanya Momtahen、Kennedy L. Queen、Ronald G. Sherrill、Jerzy Szewczyk、Timothy M. Willson、Elizabeth E. Sugg

  DOI：10.1021/jm9601664

  日期：1996.1.1

  Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC(50) = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist; of CCK-8 (pA(2) = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.